Robert S. Kerbel
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Robert S. Kerbel has a total of 236 co-authors. Here are the top co-authors by number of shared publications:
Shan Man
Biological Sciences Platform Sunnybrook Research Institute Toronto ON Canada
34 shared publicationsPing Xu
Biological Sciences Platform, Sunnybrook Research Institute, Toronto, ON, Canada; Department of Medical Biophysics, University of Toronto, Toronto, ON, Canada
28 shared publications- Kabir A. Khan
Biological Sciences Platform, Sunnybrook Research Institute, Toronto, Canada
16 shared publications Christina R. Lee
15 shared publications- Hung-Yang Kuo
Department of Oncology, Graduate Institute of Oncology, National Taiwan University Hospital, National Taiwan University College of Medicine, Taipei, Taiwan
12 shared publications - Areeba A. Qureshi
Department of Medical Biophysics, University of Toronto, Toronto, Canada
11 shared publications
Latest Publications
- Open Access
- 8 September 2025
- Published by Elsevier in Cell Reports Medicine
- Vol. 6 (9) , 102322
Modulation of fibronectin extracellular matrix enhances anti-tumor efficacy of immune checkpoint blockade
- 8 September 2025
- Published by Elsevier in Cell Reports Medicine
- Vol. 6 (9) , 102322
Open AccessModulation of fibronectin extracellular matrix enhances anti-tumor efficacy of immune checkpoint blockade
- Open Access
- 16 June 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S6 from Immunological Tolerance to Luciferase and Fluorescent Proteins Using Tol Mice Enables Development of Improved Tumor Models for Investigating Immunity and Metastasis
Primary tumor volumes of 4T1.2 Luc2/GFP before resection. As well as microscopy images of variant cell lines adapted in vitro from Tol mice.
- 16 June 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S6 from Immunological Tolerance to Luciferase and Fluorescent Proteins Using Tol Mice Enables Development of Improved Tumor Models for Investigating Immunity and Metastasis
Primary tumor volumes of 4T1.2 Luc2/GFP before resection. As well as microscopy images of variant cell lines adapted in vitro from Tol mice.
- Open Access
- 16 June 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S5 from Immunological Tolerance to Luciferase and Fluorescent Proteins Using Tol Mice Enables Development of Improved Tumor Models for Investigating Immunity and Metastasis
Extended data from brain implantation of E0771 Luc2/GFP. Including BLI of late tumor recurrences in Tol mice.
- 16 June 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S5 from Immunological Tolerance to Luciferase and Fluorescent Proteins Using Tol Mice Enables Development of Improved Tumor Models for Investigating Immunity and Metastasis
Extended data from brain implantation of E0771 Luc2/GFP. Including BLI of late tumor recurrences in Tol mice.
- Open Access
- 16 June 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S1 from Immunological Tolerance to Luciferase and Fluorescent Proteins Using Tol Mice Enables Development of Improved Tumor Models for Investigating Immunity and Metastasis
Genotyping data of Tol mice, including DNA gel electrophoresis and schematics of primer positions.
- 16 June 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S1 from Immunological Tolerance to Luciferase and Fluorescent Proteins Using Tol Mice Enables Development of Improved Tumor Models for Investigating Immunity and Metastasis
Genotyping data of Tol mice, including DNA gel electrophoresis and schematics of primer positions.
- Open Access
- 16 June 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S3 from Immunological Tolerance to Luciferase and Fluorescent Proteins Using Tol Mice Enables Development of Improved Tumor Models for Investigating Immunity and Metastasis
Loss of bioluminescence signal observed in two different immunocompetent breast tumor models.
- 16 June 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S3 from Immunological Tolerance to Luciferase and Fluorescent Proteins Using Tol Mice Enables Development of Improved Tumor Models for Investigating Immunity and Metastasis
Loss of bioluminescence signal observed in two different immunocompetent breast tumor models.
- Open Access
- 16 June 2025
- Published by American Association for Cancer Research (AACR)
Data from Immunological Tolerance to Luciferase and Fluorescent Proteins Using Tol Mice Enables Development of Improved Tumor Models for Investigating Immunity and Metastasis
There is a continuing need for improved preclinical mouse models of cancer that more accurately predict therapy outcomes for future clinical translation. Luciferase and bioluminescence have long been utilized to generate models conducive to noninvasive imaging to monitor tumor growth, disease progression, and response to therapy. However, luciferase, as well as fluorescent reporter proteins, are highly immunogenic, limiting their use in some syngeneic tumor models in immunocompetent mice. In this study, we described the utility of transgenic mice engineered to have tolerance to luciferase and several other reporter proteins, known as Tol mice, in cancer immunology research. Some tumor cell lines expressing both luciferase and GFP were completely rejected in wild-type mice but maintained robust growth in Tol mice. Additionally, Tol mice allowed the development of an experimental brain metastasis model and a postsurgical resection spontaneous metastasis model. Importantly, even when certain cell lines carrying reporter proteins successfully formed tumors in immunocompetent wild-type mice, underlying immunity existed that could be reinvigorated by immune checkpoint inhibitors. Therefore, caution is needed when using such models in wild-type mice, as exaggerated effects may be induced by immunotherapy. Tol mice circumvent this problem and will likely widen the number of orthotopic and metastatic tumor models that can be used in immunotherapy studies in both C57Bl/6 and BALB/c mice.Significance:Tol transgenic mice, tolerant to reporter proteins like luciferase and GFP, can be used to develop improved tumor models for studying metastasis and immunotherapy, avoiding immune rejection issues in immunocompetent mice.See related commentary by Grzelak and Ghajar, p. 2143
- 16 June 2025
- Published by American Association for Cancer Research (AACR)
Open AccessData from Immunological Tolerance to Luciferase and Fluorescent Proteins Using Tol Mice Enables Development of Improved Tumor Models for Investigating Immunity and Metastasis
There is a continuing need for improved preclinical mouse models of cancer that more accurately predict therapy outcomes for future clinical translation. Luciferase and bioluminescence have long been utilized to generate models conducive to noninvasive imaging to monitor tumor growth, disease progression, and response to therapy. However, luciferase, as well as fluorescent reporter proteins, are highly immunogenic, limiting their use in some syngeneic tumor models in immunocompetent mice. In this study, we described the utility of transgenic mice engineered to have tolerance to luciferase and several other reporter proteins, known as Tol mice, in cancer immunology research. Some tumor cell lines expressing both luciferase and GFP were completely rejected in wild-type mice but maintained robust growth in Tol mice. Additionally, Tol mice allowed the development of an experimental brain metastasis model and a postsurgical resection spontaneous metastasis model. Importantly, even when certain cell lines carrying reporter proteins successfully formed tumors in immunocompetent wild-type mice, underlying immunity existed that could be reinvigorated by immune checkpoint inhibitors. Therefore, caution is needed when using such models in wild-type mice, as exaggerated effects may be induced by immunotherapy. Tol mice circumvent this problem and will likely widen the number of orthotopic and metastatic tumor models that can be used in immunotherapy studies in both C57Bl/6 and BALB/c mice.Significance:Tol transgenic mice, tolerant to reporter proteins like luciferase and GFP, can be used to develop improved tumor models for studying metastasis and immunotherapy, avoiding immune rejection issues in immunocompetent mice.See related commentary by Grzelak and Ghajar, p. 2143
- Open Access
- 16 June 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S9 from Immunological Tolerance to Luciferase and Fluorescent Proteins Using Tol Mice Enables Development of Improved Tumor Models for Investigating Immunity and Metastasis
Percentage GFP positivity of engineered Luc2/GFP cells.
- 16 June 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S9 from Immunological Tolerance to Luciferase and Fluorescent Proteins Using Tol Mice Enables Development of Improved Tumor Models for Investigating Immunity and Metastasis
Percentage GFP positivity of engineered Luc2/GFP cells.
- Open Access
- 16 June 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S8 from Immunological Tolerance to Luciferase and Fluorescent Proteins Using Tol Mice Enables Development of Improved Tumor Models for Investigating Immunity and Metastasis
Extended data of B16F1 Luc2/GFP in WT vs Tol mice treated with immune checkpoint inhibitors.
- 16 June 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S8 from Immunological Tolerance to Luciferase and Fluorescent Proteins Using Tol Mice Enables Development of Improved Tumor Models for Investigating Immunity and Metastasis
Extended data of B16F1 Luc2/GFP in WT vs Tol mice treated with immune checkpoint inhibitors.
- Open Access
- 16 June 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S2 from Immunological Tolerance to Luciferase and Fluorescent Proteins Using Tol Mice Enables Development of Improved Tumor Models for Investigating Immunity and Metastasis
Gating strategies for flow cytometry analysis of B16F1 digested tumors.
- 16 June 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S2 from Immunological Tolerance to Luciferase and Fluorescent Proteins Using Tol Mice Enables Development of Improved Tumor Models for Investigating Immunity and Metastasis
Gating strategies for flow cytometry analysis of B16F1 digested tumors.
- Open Access
- 16 June 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S7 from Immunological Tolerance to Luciferase and Fluorescent Proteins Using Tol Mice Enables Development of Improved Tumor Models for Investigating Immunity and Metastasis
Analysis of Luc2+ 4T1.2 metastases in lungs from Tol mice vs WT mice.
- 16 June 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S7 from Immunological Tolerance to Luciferase and Fluorescent Proteins Using Tol Mice Enables Development of Improved Tumor Models for Investigating Immunity and Metastasis
Analysis of Luc2+ 4T1.2 metastases in lungs from Tol mice vs WT mice.